急需翻譯英翻中將此篇醫學期刊翻譯

Here, we investigated the efficacy of ALX-109, alone and in

combination with tobramycin or aztreonam, antibiotics currently

used to treat lung infections in CF patients, to disrupt and to eliminate

P. aeruginosa biofilms grown on human CF airway epithelial

cells. Inhaled tobramycin (TOBIw, Novartis) and inhaled aztreonam

(Caystonw, Gilead), the only two inhaled antibiotics approved

to treat P. aeruginosa infections in CF patients, are rapidly

eliminated from the CF lung. The concentration of both inhaled

antibiotics quickly decreases in sputum, and 2 h post-inhalation

their concentration in sputum is ,10% of the inhaled dose.32,33

We report that ALX-109 alone reduced PAO1 biofilm formation,

but had no effect on established biofilms. Importantly, ALX-109

enhanced the ability of tobramycin and aztreonam to

inhibit PAO1 biofilm formation and to reduce established PAO1

biofilms. ALX-109 and tobramycin were also additive in disrupting

established biofilms formed by six clinical isolates of

P. aeruginosa obtained from the sputum of CF patients. Mucoid

P. aeruginosa isolates were the most susceptible to the combination

of ALX-109 and tobramycin. In addition, ALX-109 also

enhanced the ability of aztreonam to reduce established PAO1

biofilms.

1 Answer

Rating
  • 5 years ago
    Favorite Answer

    這裡,我們調查的ALX-109的功效,單獨和

    用妥布黴素或氨曲南,目前抗生素結合

    用於治療肺部感染的CF患者,破壞並消除

    銅綠假單胞菌生物膜生長在人類CF呼吸道上皮

    細胞。吸入妥布黴素(TOBIw,諾華)和吸入氨曲南

    (Caystonw,Gilead公司),只有兩個吸入抗生素批准

    治療CF患者綠膿桿菌感染,正在迅速

    從CF肺消除。兩個吸入濃度

    抗生素迅速減小在痰,和2小時後的吸入

    它們在痰濃度,吸入dose.32,33 10%

    我們報告說,ALX-109獨減少PAO1生物膜的形成,

    但對建立生物膜沒有影響。重要的是,ALX-109

    增強妥布黴素和氨曲南向能力

    抑制PAO1生物膜的形成和減少建立PAO1

    生物膜。 ALX-109和妥布黴素也是添加劑破壞

    由六個臨床分離形成的生物膜成立

    銅綠假單胞菌的CF患者的痰獲得。粘液

    銅綠假單胞菌菌株是最敏感的組合

    ALX的-109和妥布黴素。此外,ALX-109還

    增強氨曲南,以減少建立PAO1的能力

    生物膜。

Still have questions? Get your answers by asking now.